RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D016019:Survival Analysis
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin